Invests primarily in American Depositary Receipts (ADRs) of GSK plc. Aims to mirror the performance of GSK plc's stock. Now — the numbers.
The stock trades 21% below its peak. The market has trimmed its expectations for the company.
It pays out $2.08 per share each year — regular cash for whoever holds the stock.
Since the drop from its peak, buyer appetite hasn’t come back.
We grade companies — revenue, margins, balance sheets. This is a fund, so there is no report card to give. That is not a low grade; it is a different kind of thing.
One-line summary: a basket, not a business. Judge it by what it holds.